Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study.

Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S (SHERPA) trial evaluated a mRNA-1273 boost after A...

Descripción completa

Detalles Bibliográficos

Autores principales:	Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline Odhiambo, Kentse Khuto, Simone I Richardson, Millicent A Omondi, Rofhiwa Nesamari, Roanne S Keeton, Catherine Riou, Thandeka Moyo-Gwete, Craig Innes, Zwelethu Zwane, Kathy Mngadi, William Brumskine, Nivashnee Naicker, Disebo Potloane, Sharlaa Badal-Faesen, Steve Innes, Shaun Barnabas, Johan Lombaard, Katherine Gill, Maphoshane Nchabeleng, Elizma Snyman, Friedrich Petrick, Elizabeth Spooner, Logashvari Naidoo, Dishiki Kalonji, Vimla Naicker, Nishanta Singh, Rebone Maboa, Pamela Mda, Daniel Malan, Anusha Nana, Mookho Malahleha, Philip Kotze, Jon J Allagappen, Andreas H Diacon, Gertruida M Kruger, Faeezah Patel, Penny L Moore, Wendy A Burgers, Kate Anteyi, Brett Leav, Linda-Gail Bekker, Glenda E Gray, Ameena Goga, SHERPA study team
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Public Library of Science (PLoS) 2024-01-01
Colección:	PLOS Global Public Health
Acceso en línea:	https://doi.org/10.1371/journal.pgph.0003260
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!